Alphabet Inc Class A vs TransMedics Group Inc — how do they compare? Alphabet Inc Class A trades at $343.79 (market cap $4.20T), while TransMedics Group Inc trades at $86.75 (market cap $3.10B). The key difference: Alphabet Inc Class A is far larger — about 1354.8× TransMedics Group Inc's market cap, and Alphabet Inc Class A pays a 0.26% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| GOOGL | TMDX | |
|---|---|---|
Market Cap | $4.20T | $3.10B |
Sector | Media | Technology |
52-Week High | $402.62 | $150.42 |
52-Week Low | $199.32 | $61.99 |
Enterprise Value | $4.09T | $3.49B |
Dividend Yield | 0.26% | — |
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOGL) is trading at $343.80, down 3.84% amid broader tech sector rotation. Despite the recent decline, the company maintains strong fundamentals with 2025 revenue of $402.84B and net income of $132.17B, representing a 32.8% profit margin. Technical indicators show bearish momentum with the stock testing support near $341, while analyst consensus remains overwhelmingly bullish with an 85% buy rating and $426.28 price target. Recent quarterly earnings have consistently exceeded expectations, with Q2 2026 EPS of $9.11 beating estimates by 217%.
The outlook remains positive given Alphabet's dominant market position, AI leadership, and strong cash flow generation. Key risks include antitrust scrutiny and tech sector volatility. With the stock trading below consensus targets and showing robust earnings growth, current levels present a potential entry point for long-term investors seeking exposure to AI and digital advertising growth.
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
Trailing returns across standard periods
Latest headlines on both assets
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →